Loading
A phase 3 trial of Capecitabine, Eribulin and Carboplatin in triple-negative breast cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer is a phase 3 interventional study registered as NCT06279364 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 524 participants planned, started 2024-02-28 and due to reach its primary completion in 2026-07. Interventions recorded: SKB264, Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin and Carboplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sichuan Kelun-Biotech, Eribulin, Capecitabine and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Capecitabine, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Eribulin, Carboplatin, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Capecitabine and the tag pipeline.
Shares Eribulin, Carboplatin, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Carboplatin and the tag pipeline.
Shares Sichuan Kelun-Biotech, Carboplatin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/